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Mesangiogenic Progenitor Cells (MPCs) are human bone marrow-derived multipotent
cells, isolated in vitro under selective culture conditions and shown to retain both
mesengenic and angiogenic potential. MPCs also co-isolated with multipotent stromal
cells (MSCs) when bone marrow primary cultures were set up for clinical applications,
using human serum (HS) in place of fetal bovine serum (FBS). MPC culture purity
(over 95%) is strictly dependent on HS supplementation with significant batch-to-batch
variability. In the present paper we screened different sources of commercially available
pooled human AB type serum (PhABS) for their ability to promote MPC production under
selective culture conditions. As the majority of “contaminating” cells in MPC cultures
were represented by MSC-like cells, we hypothesized a role by differentiating agents
present in the sera. Therefore, we tested a number of growth factors (hGF) and found
that higher concentrations of FGF-2, EGF, PDGF-AB, and VEGF-A as well as lower
concentration of IGF-1 give sub-optimal MPC recovery. Gene expression analysis of hGF
receptors was also carried out both inMSCs andMPCs, suggesting that FGF-2, EGF, and
PDGF-AB could act promoting MSC proliferation, while VEGF-A contribute to MSC-like
cell contamination, triggering MPC differentiation. Here we demonstrated that managing
hGF contents, together with applying specific receptors inhibitors (Erlotinib-HCl and
Nintedanib), could significantly mitigate the batch-to-batch variability related to serum
supplementation. These data represent a fundamental milestone in view of manufacturing
MPC-based medicinal products.
Keywords: mesangiogenic progenitor cells, mesenchymal stromal cells, human serum, growth factors, bone
marrow culture, cell-based medicinal product, Erlotinib, Nintedanib
INTRODUCTION
Mesenchymal stromal cells (MSCs) are multipotent adult progenitor cells isolated in vitro from a
plethora of different tissues (reviewed in Murray et al., 2014) as their perivascular origin has been
demonstrated and widely accepted (da Silva Meirelles et al., 2006; Crisan et al., 2008). MSC role
as skeletal tissue progenitors has been investigated in a variety of studies in animal models, and
cell-based therapy approaches demonstrated their beneficial effects in the regeneration of damaged
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skeletal tissues including bone (Watson et al., 2014), cartilage
(Richardson et al., 2015), tendons (Pacini et al., 2007), and
meniscus (Yu et al., 2015). For those reasons, most of the tissue
engineering strategies and regenerative medicine approaches,
developed to de novo skeletal tissue formation, involved MSCs
(Yousefi et al., 2016). Nonetheless, it has been reported that an
effective tissue remodeling response is in tight correlation with
the formation of vascularized tissue (Rao and Stegemann, 2013;
Hutton and Grayson, 2014). Commonly, the vascularization of
the newly formed tissues in vivo has been expected driven in
large part by the host response to the implant, and trigged by
hypoxic condition surrounding the grafted cells (Chamberlain
et al., 2015). Nonetheless, this effect could be hypothesized
in acute injuries with moderate tissue loss, but in case of
large implants or poor blood supply, as in non-union fracture
or pseudoarthrosis (Hak et al., 2014), the vascularization of
constructs would be compromised. Modular constructs obtained
applying both osteoprogenitor cells, as MSCs, and endothelial
cells (ECs) or their precursors (EPCs), have been investigated
as an option in order to sustain vascularization of the implants,
independently from the host response (Butler and Sefton, 2012).
However, MSCs have been estimated to represent around 0.001–
0.01% of human bone marrow mononuclear cells (hBM-MNCs)
(Subbanna, 2007; Lechanteur et al., 2016), and similarly ECs
and EPCs represent rare populations in their tissues of origin
(Pelosi et al., 2014), thus pre-clinical and clinical applications
of these cells, alone or in combination, require extensive ex
vivo cell expansion to obtain therapeutic cell doses. Most widely
accepted MSC isolation and expansion protocols, from bone
marrow, are based on basal media supplemented with fetal
bovine serum (FBS) (Haynesworth et al., 1992; Prockop, 1997).
Similarly, consistent fractions of FBS should be applied also in
the EC and EPC isolation (Kirton and Xu, 2010). However,
all supplements of animal origin expose patients to a number
of risks and represent a major obstacle to comply with good
manufacturing practice (GMP) guidelines (Herberts et al., 2011).
The urgent need for FBS alternatives led to consider human
serum (HS) as the straightforward substitute in clinical-grade
MSC production (Altaie et al., 2016).
In 2009, during the attempt to produce multipotent
mesenchymal stromal cells (MSCs) in xeno-free GMP-compliant
culture conditions, we had shown the occurrence of mesodermal
(currently renamed “mesangiogenic”) progenitor cells (MPCs),
in hBM-MNC cultures when using autologous serum (AS)
(Petrini et al., 2009) or pooled human AB type serum (PhABS)
(Trombi et al., 2009). MPCs have been described in vitro as slow
cycling MSC progenitors that also retain angiogenic properties
(Fazzi et al., 2011). They are characterized by peculiar fried
egg-shape morphology, expression of pluripotency-associated
markers OCT4 and NANOG, and intense nestin expression
(Pacini et al., 2010). MPCs lack mesenchymal-associated markers
CD73, CD90, and CD105 while showing occurrence of CD31,
CD11c, and CD18.
After more than 6 years spent on MPC characterization and
optimization of isolating procedures, we believe that these cells
could facing a new era and possibly being involved in skeletal
tissue engineering and regeneration. As MPCs demonstrated
in vitro retaining both mesengenic and angiogenic potential,
it reasonable hypothesizes the development of MPC-based
implants in alternative to the modular constructs. The need
of two or more different expanded cell populations giving a
mesangiogenic potential to the engineered tissues could be
overtaken applying cell populations like MPCs (Pacini and
Petrini, 2014). However, the definition of a highly reproducible
clinical-grade manufacturing process represents a first step in
dealing with a possible application of MPCs in cell-based
therapies. From the first report of mesangiogenic cells in human
bone marrow cultures applying AS, a consistent variability
in the MPC harvesting was reported. Only two out of every
three samples cultured showed detectable MPC population co-
isolated with MSCs, with percentages that could vary 10-fold
(Petrini et al., 2009). As a consequence, we believe that the
supplementation with human sera could induce considerable
culture variability, during cell manufacturing process, depending
on donor sex and age as well as diseases and pharmacological
treatments at the time of serum collection, especially in the
autologous context. Consistent production of almost pure MPC
cultures has been achieved applying commercially available
PhABS. Under these selective culture conditions it was possible
to obtain MPCs from all the samples, with recoveries showing
very low coefficient of variation (≈10%). Conversely, culturing
the same samples in FBS supplementedmedia led to cell products
constituted by MSCs only (Trombi et al., 2009). Nonetheless,
we recently reported that isolation of MPCs at high grade
of purity (over 95%) would be possible only after accurate
screening of commercially available PhABS (Montali et al.,
2016). In fact, a small number of tested batches produced
cell products with consistent percentages of MSC-like cell
population, compromising the purity of the MPC preparations.
In order to define specific sera properties, allowing the optimal
MPC manufacturing process, would be helpful the comparisons
between PhABS with good performances and PhABS promoting
MSC “contamination.”
Human serum contains a large and untreatable number of
biological active molecules possible affecting the MPC isolation
and inducing MSC proliferation (Rodrigues et al., 2010).
However, recent efforts in the establishment of serum-free media
for MSC in vitro expansion, demonstrated that human platelet
lysate (hPL) could efficiently replace serum in culture (reviewed
in Burnouf et al., 2016). This important finding narrows the
choice of essential components to platelet granules content
(Fekete et al., 2014). Platelets contain a lot of potent biological
active molecules (Semple et al., 2011), mainly stored in the α-
granules (Golebiewska and Poole, 2015), in addition to important
factors involved in coagulation. Thesemolecules include different
chemokines (Semple et al., 2011) and human growth factors
(hGFs), such as epidermal growth factor (EGF), basic fibroblast
growth factor (FGF-2), platelet derived growth factor isoforms
(PDGF-AA, -AB, and-BB), insulin-like growth factor-1 (IGF-
1), vascular endothelial growth factor (VEGF), and some others
(Nurden et al., 2008).
In order to define reproducible MPC manufacturing process,
in the present paper we moved a first step focusing on the effect
of the platelet-derived hGFs, mentioned above, on the MPC
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production. EGF, FGF-2, PDGFs, IGF-1, and VEGF have been
reported regulating proliferation and survival of BM-derived
MSCs. Thus, we hypothesize that these five hGFs or some of them
could promote expansion ofMSCs, during primary bonemarrow
cultures intended for MPC production. Here we compare six
different commercial PhABS, selected on the basis of their
different performance, attempting to correlate the percentage of
“contaminant” MSC-like cells with the serum concentration of
those hGFs.
MATERIALS AND METHODS
Screening of Human Sera for MPC
Isolation
The study has been performed according to the declaration of
Helsinki and the sample collection protocol was approved by the
ethical committee of “Azienda Ospedaliero-Universitaria Pisana”.
Bone marrow aspirates were obtained after written consent
from 8 patients (4M/4F, median age 65), undergoing orthopedic
surgery for hip replacement. Soon after femoral neck osteotomy,
approximately 10 ml of bone marrow were aspirated, using a
20ml syringe containing 500 U.I. of heparin, and promptly
sent to the cell culture facility. Samples were diluted 1:4 and
hBM-MNCs collected by density gradient centrifugation using
Ficoll-PaqueTMPREMIUM (GE Healthcare, Uppsala, Sweden).
After two washes in Dulbecco’s Modified Phosphate Buffer (D-
PBS, LifeTechnologies, Carlsbad, USA-CA) cells were plated
at 8 × 105/cm2 in hydrophobic six-well plates for suspension
culture (Greiner Bio-One, Kremsmünster, Austria) and cultured
in minimal essential medium supplemented with PhABS as
previously described (Montali et al., 2016). Briefly, low-glucose
Dulbecco’s modified Eagle medium (DMEM, LifeTechnologies)
was supplemented with 2 mM Glutamax R© (LifeTechnologies),
100 µg/mL gentamicin (LifeTechnologies), and 10% PhABS.
We tested six different commercially available PhABS (AB type
and off-the-clot) from four different manufacturers (Table 1).
Culture medium was changed every 48 h. After 7–8 days, plates
were morphologically screened for MPCs using an inverted
microscope, and cells subsequently detached by TrypLE R© Select
(LifeTechnologies) digestion and washed in D-PBS.
MSC Cell Culture
Duplicate hBM-MNC samples collected by density gradient
centrifugation were plated at 2 × 105/cm2 in gas-treated
culture plates for adherent cells. DMEM was supplemented with
2mM Glutamax R© (LifeTechnologies), 100µg/mL gentamicin
(LifeTechnologies), and 10% FBS (LifeTechnologies). Culture
mediumwas changed after 48 h to remove non-adherent cells and
refreshed twice a week.
Flow Cytometry
To identify MPCs and MSC-like cells (Keating, 2012) in
MPC primary cultures freshly detached cells were incubated
with anti-CD90 FITC-conjugated, anti-CD73 PE-conjugated,
anti-CD31 PE/Cy7-conjugated, anti-CD18 APC-conjugated,
and anti-CD45 VioBlue R© -conjugated (Miltenyi Biotec,
BergischGladbach, Germany) antibodies for 30′ at 4◦C in the
dark and washed twice in MACSQuant R© Running Buffer
(Miltenyi Biotec). Data were acquired using MACSQuant R©
flow cytometer and analyzed by MACSQuantify R© Analysis
Software (MiltenyiBiotec). MPCs were identified as
CD31+CD18+CD45lowCD73negCD90neg events and MSCs
as CD31negCD18negCD45negCD73brightCD90bright events.
Statistical analysis was performed by one-way analysis of
variance (ANOVA) test and Dunnett’s post-test for multiple
comparison. Results were expressed as mean value ± standard
error (SE).
Gene Expression
MPCs and MSCs from primary cultures were washed twice
in D-PBS, and pellets cryo-preserved in liquid nitrogen to be
processed. Total RNA extraction was performed soon after
thawing, using RNeasyMicro Kit (Qiage, Hilden, Germany)
according to manufacturer. RNA samples (100 ng) were retro-
transcribed using QuantiTect R© Reverse Transcription Kit
(Qiagen) and 2 µl samples of 10-fold cDNA dilutions were
amplified by quantitative Real Time PCR (qRT-PCR), using
iCycler-iQ5 Optical System (Bio-Rad, Hercules, USA-CA) and
SsoAdvancedSYBR Green SuperMix (Bio-Rad). Samples were
run in duplicate. Primer pairs (Sigma-Aldrich, St. Luis, USA-
MO) were designed to detect growth factor receptor genes:
BMPR1A, BMPR2, EGFR, FGFR1, FGFR2, FGFR3, IGF1R,
IGF2R, KDR, PDGFRA, PDGFRB, TGFBR1, TGFBR2, and
TGFBR3 (Supplementary Table S1). Relative quantitative analysis
was performed following 2−11Ct Livak method (Livak and
Schmittgen, 2001). Normalization was performed by using
RPL13A and ACTB housekeeping genes. Values were reported as
log-ratios of mean MPC/MSC normalized fold expression.
TABLE 1 | PhABS details.
Code Lot# Manufacturer Type Production method Gender Origin
LZM N.R.* Lonza, Basel, Switzerland AB Off-the-clot Male only USA
LZMF N.R.* Lonza, Basel, Switzerland AB Off-the-clot Not declared USA
SERL E8051213 SeraLab, West Sussex, UK AB Off-the-clot Male only USA
SIGM SLBF-3954V Sigma Aldrich, St. Luis, USA AB Off-the-clot Not declared USA
BIOW1 S10443S4190 BioWest, Nuaillé, France AB Off-the-clot Male only EU
BIOW2 S10169S4190 BioWest, Nuaillé, France AB Off-the-clot Male only EU
*N.R., Not Recorded.
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Enzyme-Linked Immunosorbent Assay
(ELISA)
Growth factor quantification was performed on 200µl aliquots of
serum batches, by colorimetric solid phase ELISA. In particular;
epidermal growth factor (EGF), fibroblast growth factor-2 (FGF-
2), and platelet-derived growth factor AB (PDGF-AB) were
quantified using Quantikine R© immunoassay kit (R&D Systems,
Minneapolis, USA-MN). Vascular endothelial growth factor A
(VEGF-A) was quantified by VEGF-A (human) BioLISA Kit
Bender MedSystems R© (Vienna, Austria) and insulin-like growth
factor-1 (IGF-1) by IGF-1 600 ELISA kit fromDRG International
(Marburg, Germany). Assays were performed according to
manufacturer. Percentages of MSC-like cells in MPC primary
cultures were correlated with growth factor concentrations in
specific sera batches by Spearman’s correlation.
Recombinant hGF Treatments during MPC
Isolation
hBM-MNCs were obtained from 4 patients (2M/2F, median
age 68) and processed for MPC isolation as described
above, applying two different sera batches: LZM, already
screened for good performance and BIOW2 that produced
cultures with consistent MSC-like cell “contamination.” LZM
cultures were also performed in presence of 50 ng/ml rhEGF
(ThermoFisher Scientific, Waltham, MA USA), 20 ng/ml
rhFGF-2 (ThermoFisher Scientific), 50 ng/ml rhPDGF-AB
(PeproTech EC Ltd., London, UK) or 50 ng/ml rhVEGF
(ThermoFisher). Combined treatments were also performed
adding rhEGF and rhFGF-2, or rhVEGF and rhPDGF-AB. In
parallel BIOW2 cultures were also supplemented with 100 ng/ml
rhIGF-1 (PeproTech EC Ltd., London, UK), 30 ng/ml rhIGF-2
(PeproTech EC Ltd.) alone or in combination. The culture
media were changed every 2 days restoring concentrations of
the hGFs. After 7 days cells were detached by TrypLE R© Select
digestion and processed for flow cytometry to quantify MPC and
MSC percentages in the cultures, as described above. Data were
collected in duplicate and reported as median values ± standard
error (SE). One-way ANOVA test, coupled with Dunnett’s
post-test, was applied to identify significant differences.
Inhibition of hGF Receptors, during
Primary Cultures
Further six bone marrow samples (4M/2F median age 68)
were processed, as described above, to obtain MPC culture in
BIOW2 sera batch with or without adding 4 nM of Erlotinib-
HCl (OSI-744, SelleckChem, Houston, USA-TX), a potent EGFR
inhibitor, and 100 nM of Nintedanib (BIBF 1120, SelleckChem)
to simultaneously inhibit VEGF, FGF, and PDGF receptors. Cell
cultures were performed in duplicate in six-well culture plates
for suspension cultures, media were changed after 48 and 72 h
restoring inhibitors concentration and at day 6 cultures were
detached for flow cytometry analysis to quantify mesenchymal
CD73+CD90+ population. Similarly and in parallel, MPC
cultures were performed applying LZM sera batch in presence
or absence of 50 nM of Linsitinib (OSI-906, SelleckChem) as
IGF-1R inhibitor. Significant differences were revealed by one-
way ANOVA test, and the inhibition index was calculated as
difference in CD73+CD90+ percentages in treated and no-
treated cultures divided by the percentage in the non-treated.
Data were collected in duplicate and reported as median values
± standard error (SE).
Inhibition of hGF Receptors, during
Mesengenic Differentiation of MPCs
Erlotinib-HCl and Nintedanib were also applied during
mesengenic differentiation of MPCs. Briefly, MPC culture in
LZM sera batch were validated for a purity higher than 95%
and re-plated at 20,000 cells/cm2 in gas-treated 6-well plates
for adherent cultures. After overnight incubation medium
was replaced with StemMACSTM MSC expansion XF medium
(Miltenyi Biotec), according to previously reported protocol
(Montali et al., 2016). In parallel, mesengenic differentiation
was performed in presence of 4 nM of Erlotinib-HCl and 100
nM of Nintedanib. Cultures were maintained changing medium
twice a week and restoring inhibitor concentration. After 7
days mesengenic differentiation was evaluated by AlamarBlue R©
reduction assay (LifeTechnologies) as previously reported (Fazzi
et al., 2011).
RESULTS
We were able to isolate and grow MPCs from hBM-
MNC primary cultures supplemented with all six PhABS
under test. Cell yields were adequate (1.20 ± 0.23 × 105
cells/well, n = 8) to perform further analysis. Cultures
supplemented with Lonza PhABS from males (LZM) or
from males and females (LZMF) showed to be constituted
almost exclusively by cells with the typical fried egg-
shape morphology that identifies MPCs (Figure 1A; Petrini
et al., 2009). Flow cytometry confirmed the characteristic
CD31+CD18+CD45lowCD73negCD90neg MPC phenotype for
over 95% of the cell population (red dots in Figure 1A) beside
a very small CD31negCD18negCD45negCD73brightCD90bright
population of MSC-like cells (blue dots in Figure 1A; Montali
et al., 2016). Similar results were obtained using SeraLab
PhABS (SERL) (Figure 1A). Sigma-Aldrich PhABS (SIGM)
supplementation resulted in the presence of occasional spindle-
shaped MSC-like cells together with a mild increase in the
percentage of MSC immunophenotype (Figure 1A). Cultures
supplemented with two lots of BioWest PhABS (BIOW1,
BIOW2) showed a large population (10–30%) of MSC-like cells,
co-isolated with MPCs. Most MSC-like cells were organized in
clusters or in colonies (white arrows in Figure 1A).
We previously defined the cut point for MPC cell production
as 95% of CD31+CD18+CD45lowCD73negCD90neg cells within
MPC primary cultures (Montali et al., 2016). Three out of the
six serum batches resulted suitable for MPC production, showing
percentages of MSC-like cells lower than 5% with no significant
variation: LZM (2.7 ± 0.6%), LZMF (3.3 ± 0.5%), SERL (3.3 ±
1.2%). SIGM was borderline (5.9 ± 1.4%), while BIOW1 and
BIOW2 turned out not to be fitting because of significantly (p <
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FIGURE 1 | Analysis of different PhABS in MPC cultures from bone marrow. (A) Six different PhABS were tested for their efficiency in the isolation of MPCs.
After 6 days of culture, LZM, LZMF, and SERL originated MPC cultures at high grade of purity. Cultures supplemented with SIGM showed rare MSC-like cells, while
BIOW1 and BIOW2 produced a number of MSC-like cells usually clustered in proliferating foci or in rounded colonies (white arrows). Purity of cultures was estimated
by flow cytometry. CD73brightCD90brightCD31neg (blue dots) percentages lower than 5.0% accounted for a good performance in MPC (red dots) production. (B)
Mean MSC/MPC ratio in LZM, LZMF, and SERL varied from 1:26 to 1:34, as opposed to 1:4 and 1:5 detected in SIGM, BIOW1, and BIOW2.
0.01 to LZM, p < 0.05 to LZMF and SERL) higher percentages
of MSC-like cells (17.7 ± 4.8% and 16.2 ± 3.9%, respectively)
resulting in MSC/MPC frequencies around 1:4–1:5 (Figure 1B).
MPCs from LZM supplemented cultures were selectively
chosen for gene expression analysis of growth factor receptors
in comparison to standard FBS-cultured MSCs. Expression of 3
out of the 14 genes analyzed was over one log higher in MSCs:
FGFR2 (−1.74 log, p < 0.05, n = 8), PDGFRA (−1.58 log, p <
0.05, n= 8), and EGFR (−1.33 log, p< 0.01, n= 8). PDGFRB and
TGFR3 were also significantly more expressed in MSCs although
at lower levels (−0.90 and −0.69 log, respectively, p < 0.05,
n = 8). Conversely, IGF2R and KDR expression was significantly
higher in MPCs, with IGF2R only over one log higher (1.27
log, p < 0.01, n = 8, Figure 2). Higher levels of IGF1R and
TGFRB2 were detected in MPCs with a confidence limit lower
than 90% (0.37 log, p = 0.373 and 0.51 log, p = 0.198, n = 8,
respectively). BMPR1A, BMPR2, FGFR1, FGFR3, and TGFRB1
showed no significant differences.
The “contamination” of MSC-like cells in MPC primary
cultures was correlated to the concentration of growth factors
in the different sera. Higher concentrations of EGF, FGF-2,
PDGF-AB and VEGF-A were consistently found in BIOW1
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FIGURE 2 | Gene expression analysis of growth factor receptor genes
in MSCs vs. MPCs. The majority of the receptor genes resulted differentially
expressed (*p < 0.05, **p < 0.01). Expression of FGFR2, PDGFRA, and EGFR
was over one log higher in MSCs. Conversely, 10-fold higher IGF2R
expression was evidenced in MPCs.
and BIOW2 that produced cultures with higher percentages
of MSC-like cells (Table 2). FGF-2 revealed a dose-dependent
correlation showing a Spearman ratio of 0.943 (p < 0.05, n = 8,
Figure 3). In order to confirm the involvement of these hGFs in
the poor performance of a pooled sera batch, we separately added
consistent amount these factors to LZM supplemented cultures.
Percentages of MSC-like cells resulted significantly increased in
the rhEGF (34.3 ± 14.0%, p < 0.01, n = 4) and rhFGF-2 (39.2
± 17.5%, p < 0.01, n = 4) treated primary cultures, respect to
LZM control (4.6 ± 1.7%, n = 4, Figure 4). Combining these
two hGFs produced similar results (40.5 ± 17.9%, n = 4), with
no significant differences respect to cultures treated with EGF
or FGF-2 separately. Conversely, adding rhVEGF (5.6 ± 1.4%,
n = 4) or rhPDGF-AB (6.4 ± 0.5%, n = 4) resulted having
no significant effects on MPC cultures when added separately.
Combination of those hGF instead showed a mild increase in
MSC-like cell percentages (11.3 ± 0.3%, p < 0.01, n = 4),
resulting in cultures with purity lower than the cut-off point
established for feasible MPC products.
Medium supplemented with BIOW2 was selected in order to
verify if higher concentration of IGFs could be related to the good
performances of feasible sera batches. A consistent reduction,
TABLE 2 | PhABS growth factor concentrations.
PhABS EGF FGF-2 PDGF-AB VEGF-A IGF-1
batch (pg/ml) (pg/ml) (pg/ml) (pg/ml) (ng/ml)
LZM 44 0.3 584 80 205
LZMF 154 2.0 1223 175 157
SERL 7 0.5 564 78 141
SIGM 42 1.1 584 78 167
BIOW1 263 7.6 1943 440 114
BIOW2 261 5.7 2000 495 132
around 50%, of the MSC “contamination” was reported in
rhIGF-1 (17.1± 0.1%, p< 0.01, n= 4) and rhIGF-2 (17.7± 0.2%,
p < 0.01, n = 4) treated cultures, alone or in combination (19.8
± 2.8%, p< 0.01, n= 4) respect to BIOW2 control (45.8± 1.6%,
n= 4, Figure 4).
The effect of high concentration of EGF, FGF-2, VEGF
and PDGFs in the poor performance of pooled sera batches,
during MPC production, was also confirmed by receptor
inhibition experiments. In fact, the addition of Erlotinib-HCl and
Nintedanib to BIOW2 cultures resulted in the 50% reduction
of the CD73+CD90+ population (mean inhibition index: 54.2
± 7.7%, p < 0.05, n = 6) at the primary cultures, producing
suitable MPC products (>95% of purity) comparable to ones
obtained applying LZM (Figure 5A). Elevated levels of IGF-1
were instead detected in the sera batches with low mesenchymal
contamination (LZM, LZMF) but the inhibition of its receptors
did not produce any detectable effect during primary culture
(Figure 5B).
Erlotinib-HCl and Nintenadib also affected the in vitro
MPCmesengenic differentiation, with a decreased AlamarBlue R©
reduction from 20 to 40% respect to control (mean inhibition
index: 22.7 ± 10.9%, p < 0.05, n = 6). Conversely, Linsitinib
produced no detectable effects (data not shown).
DISCUSSION
Ex vivo expansion of bone marrow-derived multipotent cells
requires supplementation of basal culture medium in order to
sustain cell proliferation while maintaining cell differentiation
capability (Bernardo et al., 2011). FBS-based expansion protocols
have been used in the very first clinical applications of these
promising cells (Le Blanc et al., 2004, 2008). However, safety
concerns have been raised regarding use of supplements of
animal origin in clinical-grade expansion protocols (Sensebé
and Bourin, 2008; Reinhardt et al., 2011; Sensebé et al., 2011).
Consequently, many efforts have been made to replace animal
derived supplements and reagents with human blood derivatives
as autologous serum (AS) (Stute et al., 2004), pooled human
AB serum (PhABS) (Bieback et al., 2009), platelet lysate (PL)
(Hemeda et al., 2014) or a combination of them (Kocaoemer
et al., 2007; Muraglia et al., 2015).
In this view, during the last years our group has been
focusing on the definition of a clinical grade protocol to
culture bone marrow-derived multipotent cells by replacing FBS
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FIGURE 3 | Growth factor serum content correlated with cell composition in primary cultures. Higher concentrations of EGF, FGF-2, PDGF-AB, and VEGF-A
were detected in PhABS that gave origin to cultures with higher percentages of “contaminating” MSC-like cells. Good performance in the initiation of MPC cultures at
high grade of purity correlated with elevated levels of IGF-1.
with AS or PhABS. Our efforts led to the first description
of mesangiogenic progenitor cells (MPCs) as previously not
described cell population, co-isolated in AS-supplemented MSC
cultures (Petrini et al., 2009). In parallel, a group of colleagues
demonstrated the long-term efficacy and safety of this kind of
cell products for the healing of atrophic pseudarthrosis of the
upper limb (Giannotti et al., 2013). In this paper, Authors also
hypothesized that MPCs detected in the applied cell populations,
even if at low percentage (1–10%), could contribute to the
long lasting healing (follow-up at 76 months) reported for the
eight enrolled patients. This interesting hypothesis could be
corroborated by the idea that implanted MPCs could provide
efficient tissue regeneration, differentiating into early MSCs,
as well as contribute to the vascularization of the engineered
construct due to their demonstrated angiogenic properties
(Fazzi et al., 2011). After these encouraging clinical results, we
believe thatmanufacturingMPC-basedmedicinal products could
provide a new promising tool in skeletal tissue engineering.
As MPCs have been reported being not-proliferating cells, the
expansion is not actually permitted. Nonetheless, the frequency
of MPCs has been estimated around 1% of hBM-MNCs,
which is hundred to thousand times higher respect to MSCs
(Trombi et al., 2009), leading us to hypothesized cell-based
therapies involving this non-expanded multipotent progenitors.
The possible application of not in vitro amplified cell products
carries significant advantages in terms of: (i) a reduced risk of cell
transformation, (ii) reduced cellular senescence, and (iii) reduced
exposition to bacterial and viral contamination, minimizing the
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FIGURE 4 | Managing hGF medium contents, by adding recombinant
factors, affected the sera performance during MPC isolation. Adding
rhEGF or rhFGF-2, alone or in combination, to the cultures supplemented with
good performance serum (LZM), resulted in significantly increased MSC-like
population (red bars). Under these conditions, MPC/MSC ratio was
comparable to those reported applying MSC-inducing PhABS. Treating with
rhVEGF or rhPDGF-AB had no effects on MPC isolation, but a combination of
those two hGFs produced mild but significant increase in MSC-like
counterpart. BIOW2 batch was selected as PhABS with poor performance,
evaluating the effects of rhIGF-1 and rhIGF-2 during MPC isolation. The
treatment with rhIGFs, either alone or in combination, produced a 50%
reduction of the MSC-like population (**p < 0.01, respect to control).
culture time (Schneider et al., 2010). However, this could provide
limited number of cell doses forcing to investigate any possible
clinical application of MPCs in the context of personalized cell
therapies, which involved small-scale CBMP production similar
to that described by Giannotti et al. (2013). Anyway, in the
attempt to define manufacturing conditions, selective for MPCs,
we observed large variability in MPC yield using AS as well as
different manufacturers and batches of commercial PhABS.
In general, CBMPs represent complex biological products
displaying high rate of intrinsic variability, mainly derived
from two sources: (i) process starting material and (ii) process
conditions (Williams et al., 2012). In particular for MPC-based
product, the first mentioned source of variability could not be
eliminated in the autologous context where starting materials are
obtained by different patients. Moreover, even if the variability
related to the production process could be significantly reduced
applying automated and well-controlled manufacturing process
(Liu et al., 2010; Pacini, 2014), the serum supplementation
represents an inescapable source of variability. Here we showed
such variability to correlate with some of the most important
growth factors contained in platelet lysates (Fekete et al., 2012),
whose concentrations in the serum fluctuate regardless of donors’
age, sex or production method. Best performance in MPC
production was obtained with serum concentrations of IGF-1
over 150 ng/ml combined to low levels of EGF (<160 pg/ml),
FGF-2 (<2.0 pg/ml), PDGF-AB (<1200 pg/ml), and VEGF-A
FIGURE 5 | Erlotinib-HCl in combination with Nintedanib allowed
recovering quality MPC products applying sera with poor
performance. (A) The simultaneous inhibition of EGFR, FGFRs, PDGFRs and
VEGFRs during culture of hBM-MNCs in BIOW2 serum batch, produce a 50%
reduction in the CD73+CD90+ population, leading to a cell product
comparable to once produced in LZM. (B) Conversely, the inhibition of IGF-1R
exerted by Linsitinib did not affect the MPC production.
(<180 pg/ml). Screening these five growth factors could provide a
simple means to select high quality HS batches for the production
of MPC-based CBMPs. Moreover, data presented here also
provide interesting application for Erlotinib-HCl and Nintedanib
in the production of MPC in autologous serum, where any
possible source of variability, related to fluctuations in hGF serum
concentration, could be mitigated by receptors inhibition. This
could possibly results in qualified MPC products independently
by patient sex, age, etc.
Taking in consideration only hGFs as serum factors
influencing MPC cultures, represents the mayor limit of this
study. Serum is highly complex biological fluid composed
also by many other macromolecules (i.e., cytokines and
immunoglobulins), different lipids, hormones and other small
molecules. Further investigations are needed to exhaustively
define the essential components required to produce high quality
MPC-based cell product. Anyway, here we clearly demonstrate
that managing the interactions of these hGFs with their receptors
could also represents a new tool in MSC production. In fact,
culturing bone marrow in AS, or PhABS, and in presence
of Erlotinib-HCl and Nintedanib could lead to highly purified
MPCs that could act as culture initiating cells to produce more
homogeneous and synchronized MSC cultures. Those cultures
could be easily obtained applying the same HS, by removing
receptor inhibition and supplementing with recombinant hGF
cocktail including at least EGF and FGF-2, as demonstrated
here. Our findings are in accordance with Yamaguchi et al.
that reported comparable results between FBS and PhABS, in
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MSC culture, when PhABS cultures had been supplemented
with 10 ng/ml of FGF-2 (Yamaguchi et al., 2002). However, the
extensive literature on serum supplements in MSC cultures is
very controversial. A number of authors showed no significant
differences between AS and FBS (Yamamoto et al., 2003; Spees
et al., 2004; Stute et al., 2004), while Shigeno and Ashton
obtained greater response using AS (Shigeno and Ashton, 1995),
in contrast to the extensively reported higher performances
applying FBS (Koller et al., 1998; Kuznetsov et al., 2000). It is
reasonable hypothesized that the origins of those controversial
data, in MSC manufacturing, reside in the lack of preliminary
characterization of hGF content in the HS applied. We also
believe that those inconsistencies originate from restricting focus
on MSCs, without taking into account the positive effects of the
MPC presence within the CBMP once implanted in vivo.
HS batches rich in EGF and FGF-2 apparently worsen the
production of standard monomorphic MPC cultures probably
supporting the proliferation of MSC-like cells from other distinct
and rare progenitors reported in the bone marrow. These
mesengenic progenitors could include skeletal stem cells (SSCs),
recently described as the genuine skeletal tissue stem cells (Bianco
and Robey, 2015) or CD146-positive non-stem osteoprogenitor
(Sacchetti et al., 2007). This hypothesis is validated by our
data on growth factor receptor expression. Significantly higher
levels of EGFR, FGFR2, and PDGFRA were reported in MSCs
suggesting that these specific growth factors could have trophic
effect on MSC-like cells (Ng et al., 2008) instead of inducing
MPCs to differentiate. Conversely, VEGF-A was detected at
higher concentrations in MSC-inducing sera while KDR was
more expressed in MPCs, together with TGFBR2, suggesting a
role for VEGF-A and possibly TGF-β in MPC differentiation
toward the mesenchymal lineage. IGF-1 appeared to be acting
as MPC-promoting factor as its levels were particularly high
in MPC-inducing sera LZM, LZMF, and SERL, mirroring IGF
receptor expression in MPCs.
In conclusion, we believe that MPCs represent also a
promising alternative to hBM-MNCs as culture-initiating cells
in the production of clinical grade MSCs. A purified and
well-characterized progenitor cell population cultured under
specific controlled conditions would significantly improve CBMP
reproducibility and consequently the predictability of pre-clinical
studies. MPCs are found at frequencies one to two logs higher
than the other MSC progenitors described in bone marrow.
Moreover, future clinical applications for CBMPs based on
undifferentiated and not expanded MPCs could take advantage
from their angiogenic potential that is suggestive of possible
beneficial effects on neo- or re-vascularization of target tissues. A
complete definition of the active growth factor cocktail for MPC
efficient isolation, expansion, and differentiation is still required
also in order to possibly develop specific chemically defined
media (CDM), which will eliminate the biological variability
related to the serum supplementation.
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